FDA rejects muscle disease drug application, Capricor Therapeutics (CAPR.US) plummets in pre-market trading.

Zhtng cijng APP huxn, yuy migu jingun jgu bjule gngs y kun zhm xng jru jbng zhlio yow de shnqng, Capricor Therapeutics(CAPR.US) gji yd bo di y 60%. According to the Zhitong Finance APP, due to the rejection of a deadly muscle disease treatment drug application by US regulatory agencies, the stock price of Capricor Therapeutics (CAPR.US) once plummeted over 60%.